Organ Transplant Immunosuppressant Drugs Market
Global Organ Transplant Immunosuppressant Drugs Market Size, Share & Trends Analysis Report By Drug Class (Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids, and Others), By Transplant Organ (Heart, Kidney, Lung, and Others), By Drug Type (Generic & Branded), Forecast 2020-2026 Update Available - Forecast 2024-2030
The organ transplant immunosuppressant drug market is anticipated to grow at a CAGR of more than 14% during the forecast period. Immunosuppressant drugs also known as anti-rejection drugs lower the body's ability to reject a transplanted organ by blocking the effects of the body’s natural defenses. In most of the cases, immunosuppressant drugs that are taken post-transplant include a combination of drugs and approaches based on a patient's condition. Growth in organ transplant surgeries is one of the key factors to drive organ transplant immunosuppressant drug market growth.
Moreover, factors such as advancements in tissue engineering practices and continuous evolving organ transplant techniques will significantly aid in the growth of the organ transplant immunosuppressant drugs market. However, the high-cost organ transplantation processes will restraint organ transplant immunosuppressant drug market growth. Besides, strict organ donation and transplant regulation across the globe will also a major challenge for the growth of organ transplant immunosuppressant drugs market.
Segmental Outlook
The global organ transplant immunosuppressant drugs market is segmented based on the drug class, transplant organ, and drug type. Based on the drug class, the market is sub-segmented into calcineurin inhibitors, antiproliferative agents, mTOR inhibitors, steroids, and others. Further, based on the transplant organ type, the market is sub-segmented into the heart, kidney, lung, and others. By drug type, the market is bifurcated into generic and branded drugs.
The kidney segment by the transplant organ will be the fastest-growing
The kidney segment is anticipated to grow with a significant CAGR in the organ transplant immunosuppressant drugs market. The growth of the segment is owing to the increasing kidney transplant cases across the globe. The most commonly prescribed drug after the kidney transplant consists of the combination of a calcineurin inhibitor, an antiproliferative agent, and a corticosteroid. Moreover, the cost of the immunosuppressant drugs prescribed after the transplant is also covered in most of the health insurance which in turn will also fuel the segment growth. For instance, in the US, kidney’s immunosuppressant drugs are covered under Medicare Part B for a period of 36 months after the transplant. However, as per the new rules passed in January 2020, this limit has been eliminated.
Global Organ Transplant Immunosuppressant Drugs Market Share by Transplant Organ, 2019 (%)
Regional Outlooks
The global organ transplant immunosuppressant drugs market is further segmented based on geography including North America, Europe, Asia-Pacific, and the Rest of the World. North America is expected to hold the largest market share in the organ transplant immunosuppressant drugs market during the forecast period. The growth of the organ transplant immunosuppressant drugs market in the region is owing to favorable insurance policies, well-established healthcare infrastructure, and high individual spending on healthcare. Medicare covers the transplant and immunosuppressant drugs cost after the transplant is anticipated to drive the organ transplant immunosuppressant drugs market across the region.
Global Organ Transplant Immunosuppressant Drugs Market growth, by Region 2020-2026
Asia-Pacific will augment with the fastest growth rate in the organ transplant immunosuppressant drugs market
Asia-Pacific is anticipated to show the fastest growth rate in the organ transplant immunosuppressant drugs market owing to the increasing awareness regarding organ donation and transplant procedures. Additionally, technological advancements in the healthcare infrastructure across the region are also expected to propel the growth of the organ transplant immunosuppressant drugs market. Moreover, the surge in healthcare spending by the population including middle-income classes will also significantly aid in the growth of the organ transplant immunosuppressant drugs market across the Asia-Pacific region.
Market Players Outlook
The key players of the organ transplant immunosuppressant drugs market include AstellasPharma Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Neovii Pharmaceuticals AG, Novartis AG, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including merger, and acquisition, collaborations with government, funding to the start-ups, and new product launches to stay competitive in the market.
Recent Activities
- In January 2020, AstellasPharma Inc. started the manufacturing of Prograf in Japan in its newly built facility as Toyama Technology Center of AstellasPharma Tech Co., Ltd. Prograf is the first-line immunosuppressant for organ transplantation which is currently marketed in more than 100 countries across the globe.
- In November 2019, Asahi Kasei Corp. acquired Veloxis Pharmaceuticals for $1.3 billion, a company engaged in the development and sales of immunosuppressive drugs. With the acquisition, Asahi Kasei Corp. will be able to expand its footprints in the global immunosuppressant drug market.
The Report Covers
- Market value data analysis of 2019 and forecast to 2026.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global Organ transplant immunosuppressant drugs market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
1.1. Research Business Functions and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Astellas Pharma Inc.
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. Bristol-Myers Squibb Company
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. F. Hoffmann-La Roche Ltd.
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. Neovii Pharmaceuticals AG
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Novartis AG
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.1. Opportunities
5. Market Segmentation
5.1. Global Organ Transplant Immunosuppressant Drugs Market by Drug Class
5.1.1. Calcineurin Inhibitors
5.1.2. Antiproliferative Agents
5.1.3. mTOR Inhibitor
5.1.4. Steroids
5.1.5. Others
5.2. Global Organ Transplant Immunosuppressant Drugs Market by Transplant Organ
5.2.1. Heart
5.2.2. Kidney
5.2.3. Lung
5.2.4. Others
5.3. Global Organ Transplant Immunosuppressant Drugs Market by Drug Type
5.3.1. Patented
5.3.2. Generic
6. Regional Analysis
6.1. North America
6.1.1. US
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. AbbVie Inc.
7.2. Accord Healthcare Ltd. (Intas Pharmaceuticals Ltd.)
7.3. Allnatt Pharma LLP
7.4. Asahi Kasei Corp.
7.5. Astellas Pharma Inc.
7.6. Biocon Ltd.
7.7. Bristol-Myers Squibb Co.
7.8. Cadila Healthcare Ltd.
7.9. Dr. Reddy’s Laboratories Ltd.
7.10. F. Hoffmann-La Roche Ltd.
7.11. Mylan NV
7.12. Neovii Pharmaceuticals AG
7.13. Novartis AG
7.14. Pfizer Inc.
7.15. Sanofi SA
7.16. Swiss Pharma Pvt. Ltd.
7.17. Teva Pharmaceutical Industries Ltd.
7.18. Veloxis Pharmaceuticals, Inc.
1. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
2. GLOBAL CALCINEURIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
3. GLOBAL ANTIPROLIFERATIVE AGENTS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
4. GLOBAL mTOR INHIBITOR MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
5. GLOBAL STEROIDS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
6. GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
7. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY TRANSPLANT ORGAN, 2019-2026 ($ MILLION)
8. GLOBAL HEART IMMUNOSUPPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
9. GLOBAL KIDNEY IMMUNOSUPPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
10. GLOBAL LIVER IMMUNOSUPPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
11. GLOBAL OTHERS IMMUNOSUPPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
12. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
13. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2019-2026 ($ MILLION)
14. GLOBAL PATENTED MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
15. GLOBAL GENERIC MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
16. NORTH AMERICA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
17. NORTH AMERICAN ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
18. NORTH AMERICAN ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY TRANSPLANT ORGAN, 2019-2026 ($ MILLION)
19. NORTH AMERICAN ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2019-2026 ($ MILLION)
20. EUROPE ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
21. EUROPE ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
22. EUROPE ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY TRANSPLANT ORGAN, 2019-2026 ($ MILLION)
23. EUROPE ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2019-2026 ($ MILLION)
24. ASIA-PACIFIC ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
25. ASIA-PACIFIC ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
26. ASIA-PACIFIC ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY TRANSPLANT ORGAN, 2019-2026 ($ MILLION)
27. ASIA PACIFIC ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2019-2026 ($ MILLION)
28. REST OF THE WORLD ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
29. REST OF THE WORLD ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY TRANSPLANT ORGAN, 2019-2026 ($ MILLION)
30. REST OF THE WORLD ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2019-2026 ($ MILLION)
1. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SHARE BY DRUG CLASS, 2019 VS 2026 (%)
2. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SHARE BY TRANSPLANT ORGAN, 2019 VS 2026 (%)
3. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SHARE BY DRUG TYPE, 2019 VS 2026 (%)
4. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
5. US ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
6. CANADA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
7. UK ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
8. FRANCE ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
9. GERMANY ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
10. ITALY ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
11. SPAIN ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
12. ROE ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
13. INDIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
14. CHINA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
15. JAPAN ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
16. REST OF ASIA-PACIFIC ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
17. REST OF THE WORLD ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
